VYNE Therapeutics appoints Christine Borowski, Ph.D., to board of directors effective Jan 1, 2024

VYNE Therapeutics Inc.

Appointed Dr. Christine Borowski as Class II director, effective Jan 1, 2024, for term until 2026 annual meeting.
Dr. Borowski is Vice President at Access Bio and was appointed per prior agreement from Nov 2023 private placement.
Received option to purchase 40,000 shares at $2.33/share, vesting annually over 3 years.
Will receive standard annual cash retainer of $40,000, payable quarterly, plus annual option awards.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christine Borowski

Director

VYNE · VYNE Therapeutics Inc.

Effective: 2024-01-01
Filed: January 3, 2024, 6:59 PM ET

On December 29, 2023, the Board appointed Dr. Christine Borowski to serve as a Class II director of the Company, effective as of January 1, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christine Borowski was appointed as Director at VYNE Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 29, 2023, the Board appointed Dr. Christine Borowski to serve as a Class II director of the Company, effective as of January 1, 2024

View on SEC.gov

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-000584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.